카사바사이언스! Cassava Sciences! 임상3상 FDA SPA 획득! (알츠하이머치료제, SAVA)

Phase 3 Study Initiation Still Expected Fall 2021 AUSTIN, Texas, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, announced today that it has reached agreement with the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) for both of its pivotal Phase 3 studies of oral simufilam for the treatment of patients with Alzheimer’s disease. These SPA agreements document that FDA has reviewed and agreed upon the key design features of Cassava Sciences’ Phase 3 study protocols of simufilam fo..........

원문링크 : 카사바사이언스! Cassava Sciences! 임상3상 FDA SPA 획득! (알츠하이머치료제, SAVA)